GlobalData on MSN3 天
FDA lifts clinical hold on Avidity’s lead antibody conjugate therapy trial
Two years after the US agency placed the partial clinical hold, Avidity can resume the research of del-desiran as a treatment ...
Avidity Biosciences: Good Prospects, But We Are A Little Late
Avidity Biosciences excels in antibody oligonucleotide conjugates with its stock tripling in the past year due to innovative ...
Avidity Biosciences Announces FDA Removed Partial Clinical Hold on Delpacibart Etedesiran ...
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics ...
A Game-Changer: Commonly Used Drug Could Transform Treatment of Rare Muscle Disorder
A UCL study found that lamotrigine is as effective as mexiletine for treating non-dystrophic myotonia, a rare muscle disorder ...
inceptivemind5 天
Assembly of 2D molecular structures with triptycene scaffold
Researchers at the Institute of Science Tokyo present a streamlined approach using supramolecular scaffolds. These scaffolds ...
inceptivemind5 天
What should declining Japanese cities do?
Aging societies and population decline have been on the rise globally. However, the factors that correlate with population ...
The Brighterside of News on MSN6 天
Commonly used drug could revolutionize treatment of rare muscle disorder
This latest research on non-dystrophic myotonia offers promising results for those affected by the condition. Published in ...